Phase III Clinical Study Data Demonstrating LCP-Tacro(TM)'s Comparable ... MarketWatch (press release) HORSHOLM, Denmark, Sept. 4, 2013 /PRNewswire via COMTEX/ -- Veloxis Pharmaceuticals A/S (omx:VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will ... |
